Sanofi is 1-1 in the U.K., with early access for dupilumab but a NICE 'no' for Cerdelga
admin 15th March 2017 Uncategorised 0 Sanofi is 1-1 in the U.K., with early access for dupilumab but a NICE ‘no’ for Cerdelga
esagonowsky
Wed, 03/15/2017 – 11:14
More: Sanofi is 1-1 in the U.K., with early access for dupilumab but a NICE 'no' for Cerdelga
Source: fierce